13F reference period
Q2 2026
Security Snapshot
Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share (CRBP) Institutional Ownership
CUSIP: 21833P301
13F Institutional Holders and Ownership History from Q4 2019 to Q3 2026
Institutions Reporting
107
Shares (Excl. Options)
13,766,527
Price
$9.38
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- CRBP on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 13,766,527
- Total 13F value
- $129,111,329
- Portfolio coverage rank
- 0%
- Share change
- +795,480
- Value change
- +$7,433,033
- Number of holders
- 107
- Shares outstanding
- 19,341,293
- SEC-reported price per share
- $6.82
- Insider filing price
- $6.82
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 21833P301.
- 107 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 108 to 107 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $121,158,398 to $129,111,329.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 107 institutions filings for Q2 2026.
Security key
21833P301
13F reference period
Q2 2026
13F holders
107
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
CRBP full holder history
Corbus Pharmaceuticals Holdings, Inc. SEC filings
Corbus Pharmaceuticals Holdings, Inc. company facts
Corbus Pharmaceuticals Holdings, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 21833P301:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
CRBP
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 13% | +4.2% | $24,434,598 | -$312,902 | 2,344,971 | -1.3% | Cormorant Asset Management, LP | 11 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $15,777,853 | 1,914,788 | RA Capital Management, L.P. | 23 Sep 2026 | |||
| Aberdeen Group plc | 7.5% | $10,759,045 | 1,321,750 | Aberdeen Group plc | 31 Dec 2025 | |||
| BlackRock, Inc. | 5.9% | +100% | $10,256,411 | +$6,950,814 | 1,093,434 | +210% | BlackRock, Inc. | 30 Jun 2026 |
| ORBIMED ADVISORS LLC | 5.9% | $5,307,498 | 718,200 | OrbiMed Capital LLC | 31 Dec 2024 | |||
| VANGUARD GROUP INC | 4.9% | $4,136,516 | 599,495 | The Vanguard Group | 30 Jun 2025 |
As of 30 Jun 2026, 107 institutional investors reported holding 13,766,527 shares of Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share (CRBP). This represents 71% of the company’s total 19,341,293 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
64%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 12% | 2,344,971 | 0% | 1.1% | $21,995,828 |
| ORBIMED ADVISORS LLC | 9% | 1,737,287 | 0% | 0.31% | $16,295,752 |
| BlackRock, Inc. | 6.9% | 1,331,135 | +390% | 0% | $12,486,047 |
| Aberdeen Group plc | 6.8% | 1,321,750 | 0% | 0.02% | $12,398,015 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 760,940 | +3.7% | 0% | $7,137,617 |
| Jones Hill Capital LP | 3.4% | 653,572 | 1.3% | $6,130,505 | |
| Prosight Management, LP | 3.4% | 650,000 | -6.8% | 1.1% | $6,097,000 |
| Stonepine Capital Management, LLC | 2.2% | 425,000 | +11% | 3.1% | $3,986,500 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 423,374 | +126% | 0% | $3,972,122 |
| ADAR1 Capital Management, LLC | 2.2% | 421,787 | +27% | 0.19% | $3,956,362 |
| DIADEMA PARTNERS LP | 1.6% | 301,264 | -32% | 1.1% | $2,825,856 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.5% | 293,203 | -12% | 0% | $2,750,244 |
| STATE STREET CORP | 1.3% | 254,672 | +270% | 0% | $2,388,823 |
| DIMENSIONAL FUND ADVISORS LP | 0.98% | 190,214 | +39% | 0% | $1,783,533 |
| Exome Asset Management LLC | 0.96% | 184,914 | -21% | 1.1% | $1,734,493 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 0.78% | 151,640 | -5.5% | 0% | $1,422,383 |
| JANE STREET GROUP, LLC | 0.72% | 139,133 | +90% | 0% | $1,305,068 |
| NORTHERN TRUST CORP | 0.65% | 124,906 | +201% | 0% | $1,171,618 |
| VANGUARD FIDUCIARY TRUST CO | 0.58% | 112,397 | +17% | 0% | $1,054,284 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.58% | 111,302 | +357% | 0% | $1,044,013 |
| RENAISSANCE TECHNOLOGIES LLC | 0.57% | 110,822 | -68% | 0% | $1,039,510 |
| DAFNA Capital Management LLC | 0.56% | 107,773 | 0.19% | $1,010,911 | |
| CITADEL ADVISORS LLC | 0.48% | 92,154 | -87% | 0% | $864,405 |
| Advisory Services Network, LLC | 0.47% | 89,951 | +642407% | 0.01% | $843,740 |
| MARSHALL WACE, LLP | 0.41% | 79,331 | -46% | 0% | $744,125 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Headline period
Q2 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 77,947 | $531,599 | +$310,511 | $6.82 | 11 |
| 2026 Q2 | 13,766,527 | $129,111,329 | +$7,433,033 | $9.38 | 107 |
| 2026 Q1 | 12,903,485 | $121,158,398 | +$569,311 | $9.39 | 108 |
| 2025 Q4 | 13,244,299 | $107,809,776 | +$34,670,041 | $8.14 | 100 |
| 2025 Q3 | 8,624,602 | $109,102,095 | -$2,067,263 | $12.65 | 79 |
| 2025 Q2 | 9,061,852 | $62,525,276 | -$8,932,514 | $6.90 | 78 |
| 2025 Q1 | 10,430,351 | $55,391,632 | -$13,394,437 | $5.31 | 85 |
| 2024 Q4 | 10,952,105 | $129,272,235 | -$16,308,014 | $11.80 | 98 |
| 2024 Q3 | 11,745,584 | $242,331,671 | -$44,650,435 | $20.63 | 106 |
| 2024 Q2 | 10,752,925 | $486,116,698 | +$101,256,908 | $45.25 | 107 |
| 2024 Q1 | 8,529,313 | $334,743,519 | +$310,281,997 | $39.24 | 81 |
| 2023 Q4 | 749,666 | $4,528,896 | +$40,967 | $6.04 | 32 |
| 2023 Q3 | 742,967 | $5,007,338 | +$30,936 | $6.74 | 26 |
| 2023 Q2 | 739,439 | $5,797,676 | +$132,453 | $7.84 | 28 |
| 2023 Q1 | 723,148 | $5,257,408 | +$5,257,398 | $7.27 | 28 |
| 2020 Q2 | 0 | $0 | -$5,240 | $6.82 | 0 |
| 2020 Q1 | 1,000 | $5,240 | $5.24 | 1 | |
| 2019 Q4 | 1,000 | $5,460 | $5.46 | 1 |